cyrilzakka/clinical-trials huggingface dataset:
The Effect of Discharge Training on Surgical Recovery in Oncology Patients

A randomized control trial was made to examine the effect of discharge training developed using Nursing Interventions Classification on surgical recovery in patient who underwent oncological surgery.

The concept of surgical recovery is defined as "starting activities aimed at maintaining daily life, health and well-being after surgery" and delay in surgical recovery "increasing the number of days after surgery required to start activities aimed at maintaining daily life, health and well-being after surgery". Problems such as fatigue, pain, incisional surgical site infection, loss of appetite, which are common in patients in the postoperative period, are symptoms associated with delayed surgical recovery. In addition to these symptoms, the presence of conditions such as delayed return to home / work activities need for self-care, nausea, anorexia, pain, and difficulty in moving indicate that surgical recovery is interrupted. It has been reported that delay in surgical recovery is common after surgeries such as gastrostomy, colectomy, and exploratory laparotomy.

Patients who have undergone gastric or colorectal cancer surgery should receive discharge training before returning to social life and business life. Nurses should determine the problems they may experience at home in patients who have undergone surgeries such as gastrostomy, colectomy, and exploratory laparotomy, where delay in surgical recovery is frequently reported, plan and apply discharge training for these problems, and monitor patients in terms of surgical recovery processes at home. It has been reported that this way, the surgical recovery process can be supported and delays in surgical recovery can be prevented.

This study was conducted to determine the effect of a discharge training developed using the Nursing Interventions Classification on surgical recovery in patients undergoing oncologic surgery.

It was tested the hypotheses that there was no difference between the post-intervention intervention and control groups in terms of the surgical recovery score averages in patients who had undergone oncologic surgery were tested.

Eligibility Criteria:
Inclusion Criteria:

* Ages between 18 and 75
* Stomach or colorectal surgery
* Volunteering to participate in research
* Understanding and speaking Turkish
* Having a telephone that can be reached by him or his caregiver

Exclusion Criteria:

* Responding to less than 75% of phone calls
* Not having cognitive functions in place
* Having a hearing problem
* Not having a relative to answer in case he / she cannot answer the phone
* Having complications during hospitalization (ileus, septic shock, herniation)
* Having a history of chemotherapy / radiotherapy in the last two months
* To receive chemotherapy / radiotherapy within two months after surgery
* Complications developed during surgery
* To be transferred to the intensive care unit after surgery.
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.

The main objective of this study is to evaluate the efficacy on cognitive impairment of 3 doses of AVE1625 using a new cognitive battery called Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) in schizophrenic patients.

The secondary objectives are to measure the efficacy of AVE1625 on functional capacity of the patients using a specific scale called University of California San Diego Performance-based Skills Assessment 2 (UPSA2) and to assess the safety of the compound.


Eligibility Criteria:
Inclusion Criteria:

* Outpatients with diagnosis of schizophrenia (diagnosed ≤ 35 years of age).
* Current treatment consisting exclusively of olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy for at least 2 months.

Exclusion Criteria:

* Inpatient hospitalization within past 3 months.
* Residence at the current address \< 3 months due to any instability in the disease.
* Presence of depressive symptoms.
* Past history of clinically significant violent behavior.
* Substance dependence or abuse.
* Pregnant or breast-feeding women or women not protected by effective contraceptive method of birth control.

The investigator will evaluate whether there are other reasons why a patient may not participate.
Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana

In heavy marijuana smokers, opioid receptor blockade increases the subjective and cardiovascular effects of marijuana. The current study was designed to clarify opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function for marijuana-elicited effects in heavy marijuana smokers. For this within-subject, double-blind study, a marijuana smoking procedure was designed to characterize a dose-response relationship for marijuana's subjective and cardiovascular effects under blinded conditions.


Eligibility Criteria:
Inclusion Criteria:

* Current marijuana use
* Able to perform study procedures
* Women practicing an effective form of birth control

Exclusion Criteria:

* Current repeated illicit drug use (other than marijuana)
* Presence of significant medical illness (e.g., diabetes, cardiovascular disease,hypertension, hepatitis, clinically significant laboratory abnormalities, LFTs \> 3x upper limit of normal, blood pressure \> 140/90
Patients' Willingness-to-pay of Endodontic Treatment

The aim of the present study is to determine the monetary value of endodontic treatment (primary root canal treatment) compared to the alternative treatment options, such as extraction with or without subsequent insertion of a dental implant or placement of a fixed dental prosthesis.

Endodontic treatment of teeth with irreversibly damaged pulp aim at the long-term preservation of the affected tooth. If contraindications are present and / or a patient refuse endodontic treatment, the extraction of the affected tooth is often necessary. The resulting tooth gap might be closed by inserting a dental implant or by placing a fixed dental prosthesis.

Prior studies have shown that patients' decisions in alternative treatment options depend on a variety of factors. Studies on the willingness-to-pay (WTP) are used to compare the monetary value of different therapy procedures.

Eligibility Criteria:
Participants are selected by consecutive patient sampling (total n = 200).

Inclusion Criteria:

* Patients who are in need of an primary root canal treatment and who are able to give written consent

Exclusion Criteria:

* Non-fulfillment of the inclusion criteria
* Lack of capacity to consent
* No German language skills in written and spoken language
* Age \<18 years
Psychoeducation for Hepatitis and Alcohol Behaviors

The proposed project will apply a unique, effective family-responsive psychoeducation program, PsychoEducation Responsive to Families (PERF), for Hepatitis C Virus (HCV) treatment. The goal is to demonstrate that the intervention will enlarge the eligibility of some patients for HCV treatment and help sustain others through it.

This study aims to evaluate the utility of a psychosocial intervention (PsychoEducation Responsive to Families; PERF), applied to help patients prepare for and sustain HCV treatment in the treatment setting. Through careful psychiatric diagnosis and multiple longitudinal assessments, this study will also shed further light on the course of comorbid alcohol use, drug use, and other psychiatric syndromes and their interrelationships. The proposed study combines an innovative psychoeducation program with traditional HCV patient care and education. The goal of this work is to improve treatment adherence, allowing individual drug regimens to achieve their optimal effectiveness and reach a wider patient population. Support and sustenance of patients from a psychosocial perspective while they are in treatment should also help deliver more patients to sustained suppression of HCV as well as help presently untreated patients and populations become candidates for this therapy-ultimately reducing the disease burden of increasing numbers of patients needing liver transplantation or facing imminent death.

Eligibility Criteria:
Inclusion Criteria:

1. Individuals who are seropositive for HCV as determined by ELISA test and confirmed by direct measure of viral load as part of their clinical care
2. Lack progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy)
3. Age at least 18 years
4. Identified family member(s)/significant other(s) also willing to participate in the psychoeducation groups, and
5. Ability to provide informed consent for research participation. "Family" will be defined to include biological relatives, as well as any non-biological individual or significant other considered "family" by either the ill member or his/her immediate family.

Exclusion Criteria:

1. Inability to provide informed consent such as irreversible cognitive impairment precluding participation
2. Progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy), and
3. Age \<18 years.
Orotracheal Intubation in Newborns: Videolaryngoscopy Vs Direct Laryngoscopy

The children were randomized into two groups to receive orotracheal intubation after anesthetic induction with neuromuscular blockade, either by direct laryngoscopy (DL, DL group) or by C-MAC video laryngoscopy (VL group)

prospective randomized study including newborns , requiring orotracheal intubation for surgery or mechanical ventilation in the intensive care unit. The children were randomized into two groups to receive orotracheal intubation after anesthetic induction with neuromuscular blockade, either by direct laryngoscopy (DL, DL group) or by C-MAC video laryngoscopy (VL group).

Eligibility Criteria:
Inclusion Criteria:

* newborns requiring orotracheal intubation for surgery or mechanical ventilation in the intensive care unit

Exclusion Criteria:

* age\> 01 month
The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study

The safety and efficacy evaluation of echocardiography-guided percutaneous radiofrequency ablation (Liwen prcocedure) for cardiac tumors: a single-arm, prospective, single-center clinical study.

Cardiac tumor is a rare disease in clinical practice, which is divided into primary cardiac tumor and secondary cardiac tumor, of which secondary cardiac tumor is about 20 to 40 times of primary.The clinical symptoms of cardiac tumors are complex and varied, mainly related to the size and location of tumors. Tumors often lead to blood flow obstruction, arrhythmia, systemic embolism, which seriously threaten the life of patients.At present, surgical resection is the only operation treatment. However, many cardiac tumors have lost the chance of surgery because of many reasons.

Based on previous work, we found echocardiography-guided percutaneous radiofrequency ablation (Liwen procedure) to treat cardiac tumors.This is a single-arm, prospective, single-center clinical study. After signing the informed consent letter, the patients were screened to meet the enrollment conditions and were treated with Liwen procedure for cardiac tumors. Follow-up was performed at 7 days, 30 days, 3 months, 6 months and 12 months.

Eligibility Criteria:
Inclusion Criteria:

1. Hemodynamic changes caused by cardiac tumors or patients with obvious clinical symptoms such as chest tightness, shortness of breath, palpitations, etc., or the risk of embolization of intracardial tumors;
2. Patients who cannot be completely excised by surgery, cannot tolerate surgery or refuse surgery;
3. The patient was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed the informed consent, and agreed to complete the follow-up and follow-up examination required.

Exclusion Criteria:

1. Previously documented persistent ventricular tachycardia or ventricular fibrillation, supraventricular tachycardia with hemodynamic disturbance, cardiac arrest, and high atrioventricular block;
2. Previous history of tumor or thromboembolism exfoliating organ embolism;
3. Combined with other heart diseases requiring surgical treatment;
4. Active infections should be treated with antibiotics;
5. Bleeding constitution and coagulation disorders, or anticoagulation, antiplatelet therapy contraindications;
6. Patients who are pregnant, breastfeeding or planning to become pregnant during the clinical study;
7. The disease will cause difficulties in the evaluation of treatment, such as mental illness, metabolic disease, etc.;
8. Patients who cannot tolerate general anesthesia;
9. Severe liver, kidney, lung, brain and other major organ failure;
10. There are no patients who are suitable for the injection path of Liwen operation;
11. Other diseases deemed unsuitable for inclusion by the researchers;
12. The researcher judged that the patients' dependence was poor and could not complete the study.
Effect of "Sekanjabin e Safarjali" (Quince Oxymel) in the Prevention of Migraine Attacks

The purpose of this study is to determine whether Quince Oxymel is effective in the prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.

This is a randomized, placebo-controlled, triple blinded clinical study to evaluate the effects of oral use of "Sekanjebin e Safarjali" (Quince Oxymel) in the Prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with Migraine headache aged between 15-70, after taking signed informed consent, according to the International headache society criteria for headache \[2\] are included in this trial. 45 cases with Migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to three arms by using simple randomization. Quince Oxymel, propranolol and placebo will be given as encoded, innominate bottles with the same shape and color. Quince oxymel and placebo will be prescribed as 10 cc, three times a day for 4 weeks. Frequency, duration and intensity of Migraine Attacks at the beginning time and during 4 weeks of trial, will be evaluated, as the primary outcome measures.

Eligibility Criteria:
Inclusion Criteria:

* minimum age of 18 years old
* giving a written informed consent
* having at least 2 migraine attacks per month

Exclusion Criteria:

* patients older than 70 years old
* patients with Diabetes mellitus
* patients with chronic obstructive pulmonary disease and asthma
* pregnancy
* severe depression
* patients affected by sexual disorders
* bradyarrhythmic patients
* positive history of hypersensitivity reactions to quince, ginger, propranolol or naproxen
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

This trial will be a comparative pragmatic open label feasibility randomized controlled trial of oral daily versus IV iron in anemic postpartum patients.

Two randomly assigned groups will be compared during the postpartum period:

1. Oral Iron group: Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks TID.

   IV placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride.
2. IV Iron group: Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.

2.1 Oral placebo will be given by mouth for a total of 6 weeks TID.


Eligibility Criteria:
Inclusion Criteria:

* Delivery at our institution
* Hemoglobin below 9 g/dl in postpartum day 1
* Singleton gestation

Exclusion Criteria:

* Diagnosis of malabsorptive disorder or history of gastric bypass procedure
* Known diagnosis of anemia other than iron deficiency (thalassemia, macrocytic anemia, sickle cell, etc.)
* Significant cardiovascular disease, including but not limited to myocardial infarction or unstable angina within 6 months prior to study inclusion or current history of NYHA Class III or IV congestive heart failure
* Patient has received blood transfusion or there is a plan to transfuse
* Lactose intolerance
Evaluation of the Effectiveness of Fibrous Foods, Sugar-free Gomes and Rolly Brush® in the Dental Biofilm Removal

The objective of this study was to evaluate the efficacy of three methods for removal of dental biofilm when compared to dental toothbrushing control. Twenty patients were diagnosed and randomized into four groups according to the method tested: 1) apple 2) Rolly Brush 3) chewing gum and 4) brushing control. Subjects were evaluated four times according to the method used. All were evaluated before performing any method and after using each of the four methods separately. The patient's evaluation interval was 24 hours between the use of the methods. In the first stage, they underwent a clinical examination in which the needs of supragingival scraping or definitive restorations and prophylaxis were detected. After this step, all methods of oral hygiene and the consumption of fibrous foods and chewing gum were suspended for twenty-four hours. In the second stage, with a minimum of twenty-four hours after the first, volunteers received approximately 10 ml of basic fucsin to perform a mouthwash. The dental examination was then carried out for measurement on each dental surface and the plaque index was recorded on each surface. In the latter, four evaluations were performed with at least a 24-hour interval until the patients used the four methods


Eligibility Criteria:
Inclusion Criteria:

* Good periodontal health
* Minimum of eight occlusal surfaces of premolars and molars hygienic

Exclusion Criteria:

* Less than eight occlusal surfaces
* Use of orthodontic appliance
* Use of dental prosthesis
Vitreo-papillary Traction as an Entity Identified by Optical Coherence Tomography (OCT).

Optical Coherence Tomography (OCT) is a relatively new imaging technique in ophthalmology. This clear and documented imaging identified new diseases/ observations that were not previously known.

In ophthalmology vitreo-macular adhesion, vitreo-macular traction and posterior vitreous detachment were recognized entities for a long time. On the other hand vitreo-papillary adhesion/ traction is a fairly new concept in ophthalmology that became known after the use of OCT in ophthalmology imaging. Reasons, effects and ways of treatment of vitreo-papillary traction will take some time to evolve. The case study in which this traction was documented was initiated by an observation of a persistent, tiny single retinal hemorrhage above the optic disc of an eye. The patient was completely asymptomatic because of the vitreo-papillary traction but the OCT documentation of the case was so clear and striking.

Eligibility Criteria:
Inclusion Criteria:

* any human subject that is found to have VPT by OCT.

Exclusion Criteria:

-
Effects on Cellulite Appearance

Evaluate the safety and feasibility effecting the appearance of cellulite on the thigh using CoolSculpting.


Eligibility Criteria:
Inclusion Criteria

* Female subjects \> 22 years of age and \< 65 years of age.
* Subject has clearly visible cellulite on the intended treatment area (thighs), which in the Investigator's opinion, may benefit from the treatment.
* Subject has not had weight change exceeding 5% in the preceding month.
* Subject agrees to maintain her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
* Subject has read and signed a written informed consent form.

Exclusion Criteria

* Subject has had a surgical procedure(s) in the area of intended treatment.
* Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
* Subject has had a non-invasive fat reduction, body contouring, cellulite reduction and/or skin tightening procedure in the area of intended treatment within the past 4 months.
* Presence of significant suntan in the thighs.
* Inability to avoid sun exposure in the thighs.
* Subject has a history of hernia in or adjacent to the areas to be treated.
* Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
* Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria.
* Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
* Subject has a history of bleeding disorder or is taking any medication that in the Investigator's opinion may increase the subject's risk of bruising.
* Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol.
* Subject is taking or has taken diet pills or supplements within the past month.
* Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites, that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
* Subject has an active implanted device such as a pacemaker, defibrillator, implants (e.g. buttock implants), or drug delivery system.
* Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
* Subject is lactating or has been lactating in the past 6 months.
* Subject is unable or unwilling to comply with the study requirements.
* Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
* Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma

Though it is generally accepted that exposure to sunlight is a major causative factor for skin cancer, the risk for developing melanoma is not directly linked to sun exposure such as in non-melanoma skin cancer. Therefore, a dual pathway has been proposed, distinguishing melanoma that develops on skin that is chronically exposed to sunlight from those that occur on skin that is normally protected. The risk for each type of melanoma is believed to be determined in part by genetic factors. To define these markers reproducibly, the investigators plan to establish a large cohort with comprehensive information regarding sun sensitivity (skin type), history of experienced sun exposure, skin pigmentation phenotypes, total number of nevi, and other types of skin tumors in a central European population. The investigators will obtain blood from all participants for DNA as well as serum analyses. Based on the finding that genetic variants of the melanocortin-1 receptor (MC1R) gene, associated with red hair and fair skin, have been shown to be associated with increased risk for melanoma, particularly those harboring BRAF mutations, the investigators will now focus on the study of recently discovered genetic variants associated with pigmentation. Furthermore, the investigators will study the relation of these variants with oncogenic mutations of melanoma in BRAF, RAS and c-Kit. The study of other genetic variants will follow, once a sufficiently large cohort has been established to reveal an independent genetic risk factor in a multivariate analysis including potential covariates as mentioned above. The identification of genetic risk factors for melanoma will not only help identify individuals with increased risk but also improve our understanding of the molecular background of the development of melanoma.


Eligibility Criteria:
Inclusion Criteria:

* patients with or without melanoma

Exclusion Criteria:

* HIV and Hepatitis C positive individuals.